• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Susan Escudier Reviews Value-Based Payment Programs in Cancer Care

Video

There are some similarities among various value-based payment programs for cancer care, but they are not identical, said Susan Escudier, MD, FACP, vice president, value-based care and quality programs, Texas Oncology.

There are some similarities among various value-based payment programs for cancer care, including the Oncology Care Model (OCM), but they are not identical, said Susan Escudier, MD, FACP, vice president, value-based care and quality programs, Texas Oncology.

Transcript

How did the OCM compare with other value-based payment programs from commercial payers?

They are similar in some aspects. Now, some of the payers have been a little more prescriptive [in terms of] which drugs they want us to use. I find that a little more challenging, because the way the science develops—if we make an agreement today that lasts for 5 years, it may be out of date in 1 year.

And so, that was one thing that was kind of a good thing about OCM and a bad thing about OCM is that it didn’t include the drug coverage. It was good in the sense that the physicians were not, and practices didn’t have the burden of when the new $100,000 drug came out, they weren’t afraid to give it. The downside is that’s probably why the program didn’t save as much money as they wanted it to, because those new $100,000 drugs kept coming out.

How well do the commercial payers' value-based payments align with one another?

Similar but not identical. They have similar goals, and mostly their goals are things like decreased hospital admissions, decreased emergency room [ER] admissions, and less use of advanced imaging technologies. Those seem to be similar amongst the different programs.

I think what's a bit challenging is some of them are a little better at analyzing the data and getting it to us, and some are not, and it's harder to tell how we're actually doing in the program, because, for example, one thing I would really like to see is to have more real-time information for things like hospital admissions. Because the time to intervene with that patient who is frequently hospitalized or frequent ER visit is right away. It’d be nice to have a closer interaction with the payers, because they’re getting a bill, to say, “Hey, by the way, do you know your patient is in the hospital?” Because we don't always know. Sometimes they've gone in for their cardiologist or for pneumonia or something unrelated, but then we have a chance to figure out what we can do to help them stay healthy at home instead of going to a hospital.

Related Videos
Dr Marco del Riccio
Where patients live may shape outcomes in hypertrophic cardiomyopathy, with SDOH linked to higher risks of heart failure and arrhythmias.
Michael David Chuong, MD, radiation oncologist, Miami Cancer Institute, Baptist Health South Florida
Yuman Fong, MD, cancer surgeon, City of Hope
Dr Marco del Riccio
Elena Elimova, MD, associate professor in the Department of Medicine at the University of Toronto and staff medical oncologist at Princess Margaret Hospital
Dr Eric Yang
Adam Brufsky, MD, PhD, University of Pittsburgh
Enrique Velazquez Villarreal, MD, PhD, MPH, MS, assistant professor in the department of integrative translational sciences at City of Hope
Dr Marco Del Riccio
© 2026 MJH Life Sciences
AJMC®
All rights reserved.